SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS
- 61 Downloads
We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94.
Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 courses of chemotherapy, split radiation, and limb salvage surgery. This SCMCIE94 protocol had been used in almost all the patients described in an earlier report, in whom those with non-pelvic isolated tumors and low/absent CD56 expression in Ewing sarcoma tumor cells were all long-term survivors.
The 5-year (10-year) event-free survival rate for the patients with isolated limb primary Ewing sarcoma was 78.95 ± 8.3% (68.6 ± 10.0%) and the overall survival rate was 90.7 ± 6.2% (71.1 ± 11.2%). There were no relapses before 30 months in any of these patients.
The intensified SCMCIE94 pilot protocol has been shown previously to cure patients with localized CD56-negative non-pelvic Ewing sarcoma. The present study shows that among all patients with localized extremity disease who were treated with this protocol, there were no cases of early relapse. Although our cohort was small, the difference in results from studies using other protocols is so striking, that it would seem reasonable to assume it is attributable to the changes made in the protocol itself rather than risk factors. Late relapses of isolated limb CD56-positive Ewing sarcoma suggest minimal residual disease warranting additional therapeutic approaches such as autologous stem cell rescue after Busulfan Melfelan.
KeywordsSCMCIE94 Non-metastatic Non-pelvic Limb Ewing sarcoma Treatment outcome CD56 Early relapse prevention
No funding was procured for this work.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of our center.
- 5.Ash S, Yaniv I, Toledano H, Stein J, Kollender Y, Fenig E et al (2018) Improved outcome in local Ewing Sarcoma with an intensified pilot treatment protocol SCMCIE94. J Ped Hematol Oncol 2018 (in press) Google Scholar
- 7.Dixon WJ (1993) BMDP statistical software. University of California Press, Los AngelesGoogle Scholar
- 8.Rosen G, Caparros B, Hurvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of post operative chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 110:49;1221–1230Google Scholar
- 9.Abdul-Karim FW, Buaer TW, Kilpatrick SC, Raymond KA, Siegal GP,. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE et al (2012) Recommendations for the reporting of bone tumors. Hum Path (2004)35; 1173-1178.9. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154CrossRefGoogle Scholar
- 13.Whelan J, Hackshaw A, McTienan A, Grimer R, Spooner D, Bate J et al (2008) Survival is influence by approaches to local treatmrent of Ewing sarcoma within an international randomised controlled trial:analysis of EICESS-92. Clin Sarcoma Res 8:6. https://doi.org/10.1186/s13569-018-0093-y CrossRefGoogle Scholar
- 14.Krasin MJ, Rodriguez-Galindo C, Billups CA, Davidoff AM, Neel MD, Merchant TE, Kun LE (2004) Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 60:830–838CrossRefGoogle Scholar
- 25.Reichardt P, Tabone M, Mora J et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity:re-evaluating the European labeling. Future Oncol. https://doi.org/10.2217/fon-2018-0210
- 28.Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K et al (2007) Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110:1568–1577CrossRefGoogle Scholar
- 29.EURO-E.W.I.N G. Study Committee (1999) EURO-E.W.I.N.G. 99 Study Manual—EUROpean Ewing Tumor Initiative of National Groups Ewing Tumor Studies 1999. https://www.childrensoncologygroup.org/index.php/aews0331. Accessed 22 February 2006
- 30.Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J et al, Children’s Oncology Group (2008) Prognostic factors for patients with Ewing Sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology group. Blood Cancer 51:334–338CrossRefGoogle Scholar
- 32.Whelan J, Le Delay MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N et al (2018) High-dose chemotherapy and blood autologous stem -cell rescue compared with standard chemotherapy in localized high-risk Ewing Sarcoma: results of euro-E.W.I.N.G99 and Ewing—2008. J Clin Oncol 36:31103119Google Scholar
- 33.Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA et al (1999) Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 17:180–190CrossRefGoogle Scholar
- 34.Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4–11CrossRefGoogle Scholar